Blood pressure: how to measure, manage, and treat high blood pressure (AMA #48 rebroadcast)

Full analysis

Peter Attia delivers a thorough deep-dive on blood pressure — what it is, how common high blood pressure really is (nearly half of U.S. adults by current definitions), why accurate home measurement matters far more than an office reading, and what you can realistically do about it through lifestyle and, if needed, medication. For anyone over 50, this is as directly actionable as health content gets.

What was covered

• Why blood pressure matters as much as cholesterol. Peter Attia frames high blood pressure as one of three primary drivers of atherosclerosis (alongside high apoB and smoking), a mechanical injury to the arterial wall that compounds over decades just as a high LDL burden does.

• How the numbers are defined today. Normal: systolic below 120 and diastolic below 80. Elevated: systolic 120–129. Stage 1 hypertension: systolic 130–139 or diastolic 80–89. Stage 2: systolic at or above 140 or diastolic above 90. These definitions were tightened after the 2015 SPRINT trial.

• The SPRINT and STEP trials. SPRINT (roughly 10,000 U.S. adults, stopped early after about three years) found that driving systolic below 120 versus the then-standard below 140 produced a 25% relative reduction in major cardiovascular events and a 27% reduction in all-cause mortality. A sub-analysis called SPRINT MIND found a 16% relative reduction in dementia risk. The 2021 STEP trial (about 8,500 Chinese adults aged 60–80) replicated the cardiovascular benefit — 26% relative reduction — with a similar follow-up period.

• What high blood pressure does beyond the heart. Attia emphasizes three vulnerable organs: heart, brain (stroke and dementia), and kidneys. Each 20 mm Hg rise in systolic (or 10 mm Hg in diastolic) is associated with a doubling in the risk of death from stroke or vascular disease. He also notes that kidney damage from combined hypertension and high blood sugar is, in his view, an underappreciated epidemic.

• How to measure blood pressure accurately at home. Attia is adamant that office readings are nearly worthless. He walks through the exact setup: cuff sized to the arm, bare skin only, back supported, feet flat, legs uncrossed, five minutes of silence before taking the reading, and then repeated readings. He also lists what distorts a reading: wrong cuff size, clothing under the cuff, crossed legs (adds 5–8 mm Hg), full bladder (adds 10–15 mm Hg), no rest period (can add 10–20 mm Hg), and arm held too low or too high (about 2 mm Hg per inch from heart level). He prefers manual auscultation with a stethoscope over automated cuffs, which he says consistently run high for him.

• Lifestyle levers, with rough numbers. Weight loss: roughly 1 mm Hg reduction per kilogram lost (both systolic and diastolic). Aerobic exercise (90–150 minutes per week at 65–75% of max heart rate, approximately Zone 2): up to 8 mm Hg systolic and 5 mm Hg diastolic reduction in people with hypertension. Resistance training: about 2–3 mm Hg. Isometric resistance (e.g., wall sits): up to 6 mm Hg systolic. Sodium: effect is real but heterogeneous; Attia warns that cutting to 1,500 mg per day may raise all-cause mortality per a meta-analysis from the Institute of Medicine, even while lowering systolic by 5–6 mm Hg. Poor sleep (under five hours or over ten hours a night): associated with up to a 40% increase in hypertension risk.

• First-line medications. Four classes: thiazide diuretics, calcium channel blockers, ACE inhibitors (angiotensin-converting enzyme inhibitors, which block the hormone pathway that constricts blood vessels), and ARBs (angiotensin II receptor blockers, which work similarly but on the receptor rather than the enzyme). Each can lower systolic by roughly 12–15 mm Hg and diastolic by 9–11 mm Hg. Attia says ARBs appear slightly superior to ACE inhibitors on efficacy and side effects, but ACE inhibitors are older and cheaper and often what insurers cover. Beta blockers are no longer considered first-line for primary hypertension.

Notable claims & predictions

• Peter Attia: "By the time you're 75 years of age and older, it's north of 80% — effectively for both sexes — [who have hypertension]." The overall prevalence across all adults using current definitions is about 46%.

• Peter Attia, citing meta-analysis: "Each 20 millimeter of mercury increase in systolic blood pressure and each 10 millimeter of mercury increase in diastolic blood pressure are associated with a doubling in the risk of death from stroke, heart disease or other vascular disease" — for adults aged roughly 40–70.

• Peter Attia: "I couldn't care less what my blood pressure is in the doctor's office." He trusts only his two-week home protocol of two to three readings per day under controlled conditions, and uses that data exclusively for clinical decisions.

• Peter Attia on sodium: Cutting sodium to 1,500 mg per day will "very likely reduce systolic blood pressure by 5 to 6 millimeters of mercury in somebody who already has hypertension" — but the most recent meta-analysis he had seen from the Institute of Medicine linked that level of restriction to increased all-cause mortality.

• Peter Attia on medication versus lifestyle: "These blood pressure lowering medications by themselves are larger than any single lifestyle factor. However, when you consider the sum total of all lifestyle factors, it can be at least on par with what we see pharmacologically."

• Peter Attia: "I view it as sort of catastrophic when I see people who are biohacking their way into obscurity, all the while ignoring their blood pressure."

Fact check

The 25% relative risk reduction and 27% all-cause mortality reduction from SPRINT — consistent with the published trial, which was stopped early at a median follow-up of 3.26 years. However, early stopping tends to overestimate the treatment effect; Attia does note this limitation briefly. The absolute risk differences he cites (~0.54% per year for the primary outcome, ~1.2% for all-cause mortality) are small in absolute terms, which matters for individual decision-making. Attia acknowledges this and contextualizes it as compounding over a lifetime, which is reasonable reasoning rather than an overstatement.

"By the time you're 75 and older, it's north of 80%" — broadly consistent with U.S. epidemiological data, which show hypertension prevalence above 70–80% in that age group under the post-2017 ACC/AHA definitions.

Sodium restriction to 1,500 mg and all-cause mortality — Attia attributes this to a "meta-analysis from the Institute of Medicine." This is contested territory. A 2013 IOM report did raise concerns that very low sodium intake might be harmful in some populations, but the evidence was judged insufficient to make a recommendation, not clearly causal. The claim that 1,500 mg per day increases all-cause mortality is contested and context-dependent (it may apply mainly to people with heart failure or diabetes). Attia's characterization is in the right neighborhood of the debate but somewhat stronger than what the IOM report actually concluded. Readers should not treat 1,500 mg as a firmly proven harm threshold.

ARBs being "slightly better" than ACE inhibitors across the board — Attia attributes this to an internal white paper, not published peer-reviewed literature. The head-to-head evidence in large trials (e.g., ONTARGET) is more nuanced: ARBs and ACE inhibitors show broadly similar efficacy; ARBs have fewer side effects (notably, no cough). "Slightly better across the board" overstates the certainty in published evidence, though the side-effect advantage is well-established.

No claims that clearly fail scrutiny at a high bar of confidence. The sodium mortality claim and the ARB superiority claim deserve the hedges noted above.

Why this matters for you

• Blood pressure above 50 is almost statistically inevitable without active monitoring. Half of men and 44% of women aged